Effects of Two Different Kinesiotaping Techniques in Carpal Tunnel Syndrome
ConditionCarpal Tunnel Syndrome
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorKayseri City Hospital
About this trial
This study aims to evaluate the clinical, functional, and ultrasonographic effects of two different kinesiotaping techniques added to a standard exercise and night splint program in the treatment of Carpal Tunnel Syndrome (CTS). Participants will be randomly assigned to one of three groups: the I-Strip kinesiotaping technique group, the Button Hole kinesiotaping technique group, or a control group receiving only standard therapy. The study will assess treatment outcomes over a 12-week period using high-resolution ultrasound (specifically median nerve cross-sectional area and flattening ratio) and clinical parameters to determine the most effective conservative management approach.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Willingness and ability to sign the informed consent form.
Having symptoms of carpal tunnel syndrome (hand numbness, tingling, pain) for at least 3 months.
Clinical diagnosis of mild-to-moderate carpal tunnel syndrome confirmed by physical examination (positive Phalen/Tinel tests) and a prior nerve conduction study (EMG).
Disqualifiers
Previous wrist or hand surgery.
Severe carpal tunnel syndrome on EMG (evidence of thenar atrophy or severe motor loss).
History of trauma, fracture in the wrist area, or anatomical anomalies affecting ultrasonography.
Cervical radiculopathy, polyneuropathy, diabetic neuropathy, or other concomitant upper extremity entrapment neuropathies.
Trial design
Design model
Parallel
Treatments tested in this trial
I-Strip Kinesiotaping and Standard Therapy
Other interventionApplication of the original I-Strip kinesiotaping technique combined with a standard program of tendon/nerve gliding exercises and a night splint for 12 weeks.
Button Hole Kinesiotaping and Standard Therapy
Other interventionApplication of the Button Hole kinesiotaping technique combined with a standard program of tendon/nerve gliding exercises and a night splint for 12 weeks.
Standard Exercise and Splint Therapy
Other interventionTwelve weeks of tendon/nerve gliding exercises and night splinting.
Treatment groups
90 Participants
are divided into 3 treatment groupsGroup A: I-Strip Kinesiotaping GroupExperimental treatment 2 interventions
Group B: Button Hole Kinesiotaping GroupExperimental treatment 2 interventions
Group C: Control GroupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Median Nerve Flattening Ratio (FR)
Measurements will be taken at the pisiform bone level using resolution ultrasound.
Time frame
At baseline (T0), 3rd week (T1), and 12th week (T2)2
Median Nerve Cross-Sectional Area (CSA)
Using high-resolution ultrasound, measurements will be taken in millimeters square (mm2) at the pisiform bone level.
Time frame
At baseline (T0), 3rd week (T1), and 12th week (T2)Secondary outcomes
1
Visual Analog Scale (VAS) for Pain (Rest and activity pain intensity, 0-10 cm)
Measured on a 0 to 100 mm scale (where 0 indicates no pain and 100 indicates the worst imaginable pain); higher scores indicate a worse outcome.
Time frame
At baseline (T0), 3rd week (T1), and 12th week (T2)2
Visual Analog Scale (VAS) for Numbness/Paresthesia (Median nerve trajectory, 0-10 cm)
The Visual Analog Scale (VAS) for numbness and paresthesia is a patient-reported outcome measure used to quantify the intensity of sensory disturbances along the median nerve distribution in the hand. Patients indicate the severity of their symptoms by making a mark on a 10 cm horizontal line anchored by "no numbness/paresthesia" (0 cm) and "worst imaginable numbness/paresthesia" (10 cm). The score is determined by measuring the distance in centimeters from the 0 baseline to the patient's mark. Higher scores reflect greater severity of sensory symptoms.
Time frame
At baseline (T0), 3rd week (T1), and 12th week (T2)3
Boston Carpal Tunnel Questionnaire (BCTQ) for Symptom Severity and Functional Status
Symptom Severity Scale (SSS): Consists of 11 items assessing pain, paresthesia, numbness, weakness, nocturnal symptoms, and overall symptom patterns. Each item is scored from 1 (mildest) to 5 (most severe). The final SSS score is calculated as the mean of the completed items (ranging from 1 to 5). Functional Status Scale (FSS): Consists of 8 items evaluating the difficulty experienced in performing common daily activities requiring hand function (e.g., writing, buttoning clothes, holding a book, gripping objects). Each item is scored from 1 to 5. The final FSS score is calculated as the mean of the items (ranging from 1 to 5). For both subscales, higher scores indicate worse symptom severity and greater functional impairment.
Time frame
At baseline (T0), 3rd week (T1), and 12th week (T2)4
Douleur Neuropathique 4 (DN4) Questionnaire Score
Scale from 0 to 10; higher scores indicate a greater likelihood of neuropathic pain.
Time frame
At baseline (T0), 3rd week (T1), and 12th week (T2)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: